Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2004-02-26
2011-12-06
Belyavskyi, Michail (Department: 1644)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C435S346000, C435S375000
Reexamination Certificate
active
08071371
ABSTRACT:
A method for producing a clone of an immortalized human B memory lymphocyte, comprising the step of transforming human B memory lymphocytes using Epstein Barr Virus (EBV) in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an immortalized human B memory lymphocyte capable of producing a human monoclonal antibody with a desired antigen specificity, comprising the steps of: (i) selecting and isolating a human memory B lymphocyte subpopulation; (ii) transforming the subpopulation with Epstein Barr Virus (EBV) in the presence of a polyclonal B cell activator; (iii) screening the culture supernatant for antigen specificity; and (iv) isolating an immortalized human B memory lymphocyte clone capable of producing a human monoclonal antibody having the desired antigen specificity.
REFERENCES:
patent: 4464465 (1984-08-01), Lostrom
patent: 4997764 (1991-03-01), Favera
patent: 5106738 (1992-04-01), Hanna, Jr.
patent: 7223741 (2007-05-01), Krieg
patent: 7868139 (2011-01-01), Elson et al.
patent: 2003/0026782 (2003-02-01), Krieg
patent: 2003/0191079 (2003-10-01), Krieg
patent: 2004/0087534 (2004-05-01), Krieg
patent: 2004/0087538 (2004-05-01), Krieg
patent: 2004/0106568 (2004-06-01), Krieg
patent: 2004/0142469 (2004-07-01), Krieg
patent: 2004/0143112 (2004-07-01), Krieg
patent: 2004/0152656 (2004-08-01), Krieg
patent: 2004/0152657 (2004-08-01), Krieg
patent: 2004/0162258 (2004-08-01), Krieg
patent: 2004/0162262 (2004-08-01), Krieg
patent: 2004/0171150 (2004-09-01), Krieg
patent: 2004/0181045 (2004-09-01), Krieg
patent: 2005/0059625 (2005-03-01), Krieg
patent: 0505397 (1992-09-01), None
patent: 8900607 (1989-01-01), None
patent: 9006994 (1990-06-01), None
patent: 9424164 (1994-10-01), None
patent: 9514780 (1995-06-01), None
patent: 9602555 (1996-02-01), None
patent: 9818810 (1998-05-01), None
patent: 2007068758 (2007-06-01), None
US 6,008,200, 12/1999, Krieg (withdrawn)
Banchereau, J. et al; Growing human B lymphocytes in the CD40 system, Nature 353: 678-679, (1991).
Tsuchiyama et al; “Synergy between anti-CD40 MAb and Epstein-Barr virus in activation and transformation of human B lymphocytes.”,“Human Antibodies 8: 43-47”, (1997).
Madec, A.M., et al; Four IgG anti-islet human monoclonal antibodies isolated from a type 1 diabetes patient recognize distinct epitopes of glutamic acid decarboxylase 65 and are somatically mutated, Journal of Immunology 156:3541-9, (1996).
Peyron, E. et al; Human monoclonal autoantibodies specific for theBullous pemphigoidantigen 1 (BPAg 1). Journal of Immunology 153: 1333-1339 (1994).
Visco, V. et al; Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1., Journal of Immunology 157:956-62. (1996).
Bernasconi, et al; Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells, Science 298: 2199-2202 (2002).
Jung, et al; Distinct Response of Human B Cell Subpopulations in Recognition of an Innate Immune Signal, CpG DNA, J. Immunol. 169: 2368-2373 (2002).
Tangye, et al; A Division-Linked mechanism for the Rapid Generation of Ig-Secreting Cells From Human Memory B Cells, J. Immunol. 170: 261-269 (2003).
Tangye, et; Intrinsic Differences in the Proliferation of Naive and Memory Human B Cells as a Mechanism of Enhanced Secondary Immune, J. Immunol. 170: 686-694 (2003).
Baba, et al; Human Neutralizing Monoclonal Antibodies of the igG1 Subtype Protect Against Mucosal Simian-Human Immunodeficiency Virus Infection, Nature Medicine 6: 200-206 (2000).
Niedbala et al; A Comparison of Three Methods for Production of Human Hybridomas Secreting Autoantibodies, Hybridoma 17: 299-304 (1998).
Mulder et al; A Human Monoclonal Antibody, Produced Following In Vitro Immunization, Recognizing An Epitope Shared by HLA-A2 Subtypes and HLA-A28 Tissue Antigens, Tissue Antigens, 42: 27-34 (1993).
Drosten et al; Identification of a novel Coronavirus in Patients with Severe Acute Respiratory Syndrome, New England Journal of Medicine, 348: 1967-1976 (2003).
Takeda et al. (2003). Toll-like receptors. Annu Rev Immunol 21, 335-376.
Bron et al. (1984). “Production of human monoclonal IgG antibodies against Rhesus (D) antigen.” Proc Natl Acad Sci U S A 81(10): 3214-7.
Casali et al. (1986). “Human monoclonals from antigen-specific selection of B lymphocytes and transformation by EBV.” Science 234(4775): 476-9.
Diebold et al. (2004). Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA. Science. Feb. 19, 2004 [Epub ahead of print].
Thompson et al. (1986). “The efficient production of stable, human monoclonal antibody-secreting hybridomas from EBV-transformed lymphocytes using the mouse myeloma X63-Ag8.653 as a fusion partner.” J Immunol Methods 94 (1-2): 7-12.
Giachino et al. (1995) “kappa+lambda+ dual receptor B cells are present in the human peripheral repertoire.” J Exp Med 181, 1245-50.
Hartmann et al. (2000). “Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.” J Immunol 164(3): 1617-24.
Heil et al. (2004). Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8. Science. Feb. 19, 2004 [Epub ahead of print].
Steinitz et al. (1984). “Human anti-pneumococci antibody produced by an Epstein Barr virus (EBV)-immortalized cell line.” J Immunol 132(2): 877-82.
Ifversen et al. (1993). “Effect of cell-derived growth factors and cytokines on the clonal outgrowth of EBV-infected B cells and established lymphoblastoid cell lines.” Hum Antibodies Hybridomas 4(3): 115-23.
Johanson et al. (1997). “Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncythial virus.” J Infect Dis 176: 1215-24.
Karber (1931). “50% end-point calculation”. Arch. Exp. Pathol. Pharmak. 162, 480-483.
Kohler & Milstein (1975). “Continuous cultures of fused cells secreting antibody of predefined specificity.” Nature 256 (5517): 495-7.
Kozbor & Roder (1981). “Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique.” J Immunol 127(4): 1275-80.
Kozbor et al. (1982). “Human anti-tetanus toxoid monoclonal antibody secreted by EBV-transformed human B cells fused with murine myeloma.” Hybridoma 1(3): 323-8.
Krieg (2002). “CpG motifs in bacterial DNA and their immune effects.” Annu Rev Immunol 20: 709-60.
Krieg et al. (1995). “CpG motifs in bacterial DNA trigger direct B-cell activation.” Nature 374(6522): 546-9.
Ksiazek et al. (2003). “A novel coronavirus associated with severe acute respiratory syndrome” N Engl J Med 348 (20):1953-66.
Lanzavecchia (1985). “Antigen-specific interaction between T and B cells.” Nature 314(6011): 537-9.
Lundgren et al. (1983). “Monoclonal anti-parasite and anti-RBC antibodies produced by stable EBV-transformed B cell lines from malaria patients.” J Immunol 131(4): 2000-3.
Medzhitov & Janeway (2000). “Innate immune recognition: mechanisms and pathways.” Immunol Rev 173:89 97.
Medzhitov & Janeway (2002). “Decoding the patterns of self and nonself by the innate immune system” Science 296:298-300.
Rosen et al. “Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro.” Nature 267 (5607): 52-4.
Rosen et al. (1983). “Human monoclonal antibodies to a genus-specific chlamydial antigen, produced by EBV-transformed B cells.” J Immunol 130(6): 2899-902.
Schneider et al. (1999) “BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth”. J Exp Med 189(11):1747-56.
Steinitz et al. (1980). “Continuous production of monoclonal rheumatoid factor by EBV-transformed lymphocytes.” Nature 287(5781)
Belyavskyi Michail
Bennett Dennis A.
Humabs LLC
Mirmira Suman R.
LandOfFree
Monoclonal antibody production by EBV transformation of B cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibody production by EBV transformation of B cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody production by EBV transformation of B cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4313566